The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

SureCN1170429     [3-(1- dimethylaminoethyl)phenyl] N-ethyl-N...

Synonyms: ACMC-20m8jm, CHEBI:349928, CTK0G5184, AR-1L3125, AC1L1JK6, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of C11766

  • Potentially adaptive functional changes in cognitive processing for patients with multiple sclerosis and their acute modulation by rivastigmine [1].
  • The less severe worsening of cognition after withdrawal of treatment in patients previously treated with rivastigmine suggests an effect on disease progression [2].
  • These data show that the reduction by Rivastigmine of the immediate and long-term sequelae of brain injury are mediated by increased cholinergic activity at both muscarinic and nicotinic receptors [3].
  • Rivastigmine (2 mg/kg) reduced cerebral edema by at least 50% (p < 0.01), 24 h after CHI and accelerated the recovery of motor function 7 and 14 days after CHI [3].
  • For some cholinesterase inhibitors, such as rivastigmine, the cholinergic adverse effects such as nausea, vomiting, dizziness, diarrhoea and abdominal pain can be reduced by slowing the rate of dose titration [4].

Psychiatry related information on C11766

  • Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study [5].
  • FINDINGS: Patients taking rivastigmine were significantly less apathetic and anxious, and had fewer delusions and hallucinations while on treatment than controls [5].
  • Compared to placebo, rivastigmine produced only a small and non-significant improvement in task accuracy across all conditions with no change in response latency, and increased activity in the extrastriate visual cortex in areas associated with visual and spatial attention but not in any region within the working memory network [6].
  • Rivastigmine also inhibits BuChE, which could lead to additional benefits in late-stage Alzheimer's disease, but also cause more GI side effects at initiation of therapy [7].
  • RESULTS: For the group of patients as a whole, there was a significant improvement in short term memory and orientation during rivastigmine treatment [8].

High impact information on C11766


Chemical compound and disease context of C11766


Biological context of C11766

  • CONCLUSION: A noncompartmental approach and a compartmental approach based on a population pharmacokinetic model with Michaelis-Menten elimination yielded comparable values, 71.7% and 60.2% respectively, for the absolute bioavailability of a single 6 mg oral dose of rivastigmine [17].
  • Plasma concentrations of the major metabolite, NAP 226-90, formed by the hydrolysis of rivastigmine by cholinesterase are lower than those of the parent compound following oral and intravenous administration [17].
  • Donepezil and tacrine are highly protein bound, whereas protein binding of rivastigmine and galantamine is less than 40% [18].
  • In contrast, concomitant medication with various drugs with rivastigmine does not seem to cause any drug interactions in patients with Alzheimer's disease [4].
  • CONCLUSIONS: MTLA and the APOE genotype are not clinically useful predictors of cognitive response in subjects with probable AD who are treated with rivastigmine [19].

Anatomical context of C11766


Associations of C11766 with other chemical compounds


Gene context of C11766


Analytical, diagnostic and therapeutic context of C11766


  1. Potentially adaptive functional changes in cognitive processing for patients with multiple sclerosis and their acute modulation by rivastigmine. Parry, A.M., Scott, R.B., Palace, J., Smith, S., Matthews, P.M. Brain (2003) [Pubmed]
  2. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial. Farlow, M., Potkin, S., Koumaras, B., Veach, J., Mirski, D. Arch. Neurol. (2003) [Pubmed]
  3. Rivastigmine, a brain-selective acetylcholinesterase inhibitor, ameliorates cognitive and motor deficits induced by closed-head injury in the mouse. Chen, Y., Shohami, E., Constantini, S., Weinstock, M. J. Neurotrauma (1998) [Pubmed]
  4. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology. Nordberg, A., Svensson, A.L. Drug safety : an international journal of medical toxicology and drug experience. (1998) [Pubmed]
  5. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. McKeith, I., Del Ser, T., Spano, P., Emre, M., Wesnes, K., Anand, R., Cicin-Sain, A., Ferrara, R., Spiegel, R. Lancet (2000) [Pubmed]
  6. Neural correlates of adjunctive rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind fMRI study. Kumari, V., Aasen, I., ffytche, D., Williams, S.C., Sharma, T. Neuroimage (2006) [Pubmed]
  7. The new cholinesterase inhibitors for Alzheimer's disease, Part 1: their similarities are different. Stahl, S.M. The Journal of clinical psychiatry. (2000) [Pubmed]
  8. Prediction of treatment response to rivastigmine in Alzheimer's dementia. Adler, G., Brassen, S., Chwalek, K., Dieter, B., Teufel, M. J. Neurol. Neurosurg. Psychiatr. (2004) [Pubmed]
  9. Cognitive deficit associated with cholinergic and nerve growth factor down-regulation in experimental allergic encephalomyelitis in rats. D'Intino, G., Paradisi, M., Fernandez, M., Giuliani, A., Aloe, L., Giardino, L., Calzà, L. Proc. Natl. Acad. Sci. U.S.A. (2005) [Pubmed]
  10. The effect of drugs for Alzheimer disease assessed by means of neuroradiological techniques. Modrego, P.J. Current medicinal chemistry (2006) [Pubmed]
  11. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months. Darreh-Shori, T., Almkvist, O., Guan, Z.Z., Garlind, A., Strandberg, B., Svensson, A.L., Soreq, H., Hellström-Lindahl, E., Nordberg, A. Neurology (2002) [Pubmed]
  12. The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system. Santos, M.D., Alkondon, M., Pereira, E.F., Aracava, Y., Eisenberg, H.M., Maelicke, A., Albuquerque, E.X. Mol. Pharmacol. (2002) [Pubmed]
  13. Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease. Kaasinen, V., Någren, K., Järvenpää, T., Roivainen, A., Yu, M., Oikonen, V., Kurki, T., Rinne, J.O. Journal of clinical psychopharmacology. (2002) [Pubmed]
  14. Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Farlow, M.R., Hake, A., Messina, J., Hartman, R., Veach, J., Anand, R. Arch. Neurol. (2001) [Pubmed]
  15. The cholinergic hypothesis of Alzheimer's disease: a review of progress. Francis, P.T., Palmer, A.M., Snape, M., Wilcock, G.K. J. Neurol. Neurosurg. Psychiatr. (1999) [Pubmed]
  16. Antiamnesic and neuroprotective effects of donepezil against learning impairments induced in mice by exposure to carbon monoxide gas. Meunier, J., Ieni, J., Maurice, T. J. Pharmacol. Exp. Ther. (2006) [Pubmed]
  17. Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type. Hossain, M., Jhee, S.S., Shiovitz, T., McDonald, C., Sedek, G., Pommier, F., Cutler, N.R. Clinical pharmacokinetics. (2002) [Pubmed]
  18. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Jann, M.W., Shirley, K.L., Small, G.W. Clinical pharmacokinetics. (2002) [Pubmed]
  19. Medial temporal lobe atrophy and APOE genotype do not predict cognitive improvement upon treatment with rivastigmine in Alzheimer's disease patients. Visser, P.J., Scheltens, P., Pelgrim, E., Verhey, F.R. Dementia and geriatric cognitive disorders. (2005) [Pubmed]
  20. Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans. Kennedy, J.S., Polinsky, R.J., Johnson, B., Loosen, P., Enz, A., Laplanche, R., Schmidt, D., Mancione, L.C., Parris, W.C., Ebert, M.H. Journal of clinical psychopharmacology. (1999) [Pubmed]
  21. Gender differences in the effect of rivastigmine on brain cholinesterase activity and cognitive function in rats. Wang, R.H., Bejar, C., Weinstock, M. Neuropharmacology (2000) [Pubmed]
  22. Motor cortex hyperexcitability to transcranial magnetic stimulation in Alzheimer's disease. Di Lazzaro, V., Oliviero, A., Pilato, F., Saturno, E., Dileone, M., Marra, C., Daniele, A., Ghirlanda, S., Gainotti, G., Tonali, P.A. J. Neurol. Neurosurg. Psychiatr. (2004) [Pubmed]
  23. Rivastigmine antagonizes deficits in prepulse inhibition induced by selective immunolesioning of cholinergic neurons in nucleus basalis magnocellularis. Ballmaier, M., Casamenti, F., Scali, C., Mazzoncini, R., Zoli, M., Pepeu, G., Spano, P.F. Neuroscience (2002) [Pubmed]
  24. Absorption of rivastigmine from different regions of the gastrointestinal tract in humans. Lee, L., Hossain, M., Wang, Y., Sedek, G. Journal of clinical pharmacology. (2004) [Pubmed]
  25. Cerebral glucose metabolism, cerebrospinal fluid-beta-amyloid1-42 (CSF-Abeta42), tau and apolipoprotein E genotype in long-term rivastigmine and tacrine treated Alzheimer disease (AD) patients. Stefanova, E., Blennow, K., Almkvist, O., Hellström-Lindahl, E., Nordberg, A. Neurosci. Lett. (2003) [Pubmed]
  26. Serotonin depletion results in a decrease of the neuronal activation caused by rivastigmine in the rat hippocampus. Kornum, B.R., Weikop, P., Moller, A., Ronn, L.C., Knudsen, G.M., Aznar, S. Brain Res. (2006) [Pubmed]
  27. A stability indicating LC method for rivastigmine hydrogen tartrate. Rao, B.M., Srinivasu, M.K., Kumar, K.P., Bhradwaj, N., Ravi, R., Mohakhud, P.K., Reddy, G.O., Kumar, P.R. Journal of pharmaceutical and biomedical analysis. (2005) [Pubmed]
  28. Rivastigmine in subcortical vascular dementia: an open 22-month study. Moretti, R., Torre, P., Antonello, R.M., Cazzato, G., Bava, A. J. Neurol. Sci. (2002) [Pubmed]
  29. The age-related down-regulation of the growth hormone/insulin-like growth factor-1 axis in the elderly male is reversed considerably by donepezil, a drug for Alzheimer's disease. Obermayr, R.P., Mayerhofer, L., Knechtelsdorfer, M., Mersich, N., Huber, E.R., Geyer, G., Tragl, K.H. Exp. Gerontol. (2005) [Pubmed]
  30. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease. Bullock, R., Bergman, H., Touchon, J., Gambina, G., He, Y., Nagel, J., Lane, R. Current medical research and opinion. (2006) [Pubmed]
  31. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy. Wilkinson, D.G., Francis, P.T., Schwam, E., Payne-Parrish, J. Drugs & aging. (2004) [Pubmed]
WikiGenes - Universities